A Pilot Methodology Study To Evaluate Changes In Bone Quality Parameters Following Therapy With Recombinant Human Parathyroid Hormone, PTH (Forteo)

Pfizer1 site in 1 country20 target enrollmentDecember 2006

ConditionsOsteoporosis

InterventionsForteo

DrugsForteo

Overview

Phase: Not Applicable
Intervention: Forteo
Conditions: Osteoporosis
Sponsor: Pfizer
Enrollment: 20
Locations: 1
Primary Endpoint: Changes in bone quality parameters (micro- and macroarchitecture) in osteoporotic postmenopausal women following 12 months of therapy with Forteo
Status: Completed
Last Updated: 17 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

This methodology trial will be conducted in patients with osteoporosis and will measure the changes in bone quality parameters, micro- and macroarchitecture, bone biomarkers and bone density following therapy with the approved drug, Forteo.

Registry

clinicaltrials.gov

Start Date

December 2006

End Date

April 2008

Last Updated

17 years ago

Study Type

Interventional

Study Design

Single Group

Sex

Female

Investigators

Sponsor

Pfizer

Eligibility Criteria

Inclusion Criteria

•Postmenopausal women with osteoporosis

Exclusion Criteria

•Any therapies or products affecting bone turnover within 12 months of Screening.
•Bisphosphonate treatment \>1 month in total duration at any time in the past.
•In addition, patients must be bisphosphonate-treatment-free for at least 12 months prior to Screening.